Imatinib has minimal effects on inflammatory and osteopenic phenotypes in a murine cherubism model.

The in vivo administration of imatinib had a minimal therapeutic impact in cherubism mutant mice. To establish better pharmaceutical interventions, it is necessary to integrate new findings from murine models with clinical data from patients with a definitive diagnosis of cherubism.